- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05454332
The Caffeine Therapy in the Fetal to Neonatal Transition
The Caffeine Therapy in the Fetal to Neonatal Transition in Preterms
Introduction: The caffeine is used in the treatment for apnea of prematurity and it has several positive effects in the neurodevelopment of preterm babies. There are innumerable observational studies suggesting that initiating caffeine in the first hours of life may offer more benefits in the reduction of the necessity of intubation and in ventilation time. It is necessary to expand further research on the best time to start caffeine, which may improve the quality of care for premature infants.
Objective: To evaluate the benefits of caffeine administration in the first two hours of life compared to administration at 24 hours of life in premature patients on noninvasive mechanical ventilation with birth weights less than 1250 grams.
Methodology: Preterm newborn patients with birth weight < 1250 grams born at Hospital de Clínicas de Porto Alegre who are not intubated in the delivery room will be included. Patients will be randomized into two groups. One arm of the study will receive caffeine at 2 hours of age and the other arm will receive caffeine at 24 hours of age (control). Patients in the control group will receive 0.9% SF at 2 hours of life in order to keep the study blinded. The following outcomes will be evaluated: need for intubation, time on invasive and non-invasive mechanical ventilation, BPD, necrotizing enterocolitis, need for ROP treatment, PDA with hemodynamic repercussions, peri-intraventricular hemorrhage, leukomalacia and death. The sample size calculation is 50 patients, 25 in each arm.
Expected Results: It is expected to find a 43% reduction in the need for intubation in preterm infants who receive caffeine in the first two hours of life compared to administration at 24 hours of life. It is also expected to find a reduction in mechanical ventilation time, in addition to a possible reduction in negative outcomes associated with prematurity.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Gabriela Trindade
- Phone Number: +55 51 985002009
- Email: gabs.trindade@gmail.com
Study Locations
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-903
- Recruiting
- Hospital de Clinicas de Porto Alegre
-
Contact:
- Gabriela Trindade
- Phone Number: +55 51 985002009
- Email: gabs.trindade@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Premature newborns with birth weight less than 1250 grams who are not intubated in the delivery room, born at the Hospital de Clínicas de Porto Alegre between March 2022 and June 2023.
Exclusion Criteria:
- Premature newborns from other hospitals, with the presence of a major congenital malformation or genetic syndrome, and newborns without parental consent will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Early Caffeine Group
Group administering caffeine in the first 2 hours of life.
Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day.
|
Blinding will be done with the administration of saline solution.
Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day.
Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day.
The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution.
The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered.
The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription.
The administration will be blinded.
|
Active Comparator: Control Group
Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day.
|
Blinding will be done with the administration of saline solution.
Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day.
Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day.
The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution.
The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered.
The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription.
The administration will be blinded.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Necessity of intubation
Time Frame: first week of life
|
Noninvasive ventilation failure will be defined as intubation in the first seven days of life with the need for invasive ventilation for at least 24 hours.
|
first week of life
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
mechanical ventilation time
Time Frame: until first successful extubation (followed up at least until 36 weeks of corrected age, discharge or death)
|
Mechanical ventilation time will be counted until first successful extubation (at least 24 hours extubated)
|
until first successful extubation (followed up at least until 36 weeks of corrected age, discharge or death)
|
Bronchopulmonary dysplasia
Time Frame: followed up at least until 36 weeks of corrected age, discharge or death.
|
Bronchopulmonary dysplasia will be defined as need for O2 or ventilatory support at 36 weeks corrected gestational age.
|
followed up at least until 36 weeks of corrected age, discharge or death.
|
Intracranial hemorrhage
Time Frame: followed up at least until 36 weeks of corrected age, discharge or death.
|
Intracranial hemorrhage will be defined as intracranial hemorrhage grade 3.
|
followed up at least until 36 weeks of corrected age, discharge or death.
|
Retinopathy of prematurity
Time Frame: followed up at least until 36 weeks of corrected age, discharge or death.
|
Retinopathy of prematurity will be defined with ROP requiring treatment.
|
followed up at least until 36 weeks of corrected age, discharge or death.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Lung Diseases
- Infant, Newborn, Diseases
- Lung Injury
- Infant, Premature, Diseases
- Ventilator-Induced Lung Injury
- Bronchopulmonary Dysplasia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Purinergic Antagonists
- Purinergic Agents
- Phosphodiesterase Inhibitors
- Purinergic P1 Receptor Antagonists
- Central Nervous System Stimulants
- Caffeine
Other Study ID Numbers
- 2021-0463
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mechanical Ventilation Complication
-
Assiut UniversityNot yet recruitingMechanical Ventilation Complication | Anesthesia ComplicationEgypt
-
Hospital San Carlos, MadridFundación de Investigación Biomédica - Hospital Universitario de La PrincesaRecruitingMechanical Ventilation ComplicationSpain
-
Royal Brompton & Harefield NHS Foundation TrustRecruitingMechanical Ventilation ComplicationUnited Kingdom
-
Fundación de Investigación Biomédica - Hospital...Maquet Critical CareRecruitingMechanical Ventilation ComplicationSpain
-
Centre hospitalier de l'Université de Montréal...RecruitingMechanical Ventilation ComplicationCanada
-
Benha UniversityCompletedMechanical Ventilation ComplicationEgypt
-
Alexandria UniversityCompleted
-
Rush University Medical CenterCompletedMechanical Ventilation ComplicationUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...TerminatedMechanical Ventilation ComplicationNetherlands
-
Dr Cipto Mangunkusumo General HospitalActive, not recruitingMechanical Ventilation ComplicationIndonesia
Clinical Trials on Early Caffeine administration
-
Loyola UniversityRecruitingStress | Infant DevelopmentUnited States
-
State University of New York at BuffaloCompleted
-
Laval UniversityRecruitingOxygen Deficiency | COPD ExacerbationCanada
-
NICHD Neonatal Research NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development...Active, not recruitingApnea of PrematurityUnited States
-
NobelpharmaCompleted
-
Wayne State UniversityUnknownOpioid Dependence | Opioid Use | Bone FractureUnited States
-
Morten Hostrup, PhDActive, not recruiting
-
National Institute of Diabetes and Digestive and...CompletedDiabetes Mellitus, Type 2
-
Universidad Francisco de VitoriaUniversidad de Granada; Universidad Rey Juan Carlos; Camilo Jose Cela UniversityCompleted
-
University of LjubljanaCompletedHeart Rate Variability | Newborn | Caffeine | Apnoea of NewbornSlovenia